标题 |
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
Nivolumab联合ipilimumab与基于卡铂的双联疗法作为年龄≥70岁或ECOG体能状态为2级的晚期非小细胞肺癌患者的一线治疗对比(GFPC 08-2015 ENERGY):一项随机、开放标签、3期研究
|
网址 | |
DOI |
10.1016/S2213-2600(24)00264-9
doi
|
求助人 | |
下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |